Eledon Pharmaceuticals (NASDAQ: ELDN) announced new positive Phase 2 clinical trial results Monday showing that its investigational kidney transplant therapy, tegoprubart, delivered sustained improvements in patient-reported quality of life and transplant-related symptoms compared with tacrolimus, a commonly used immunosuppressive treatment.
The findings, presented at the American Society of Nephrology’s Kidney Week 2026 meeting in Denver, add to previously reported results from Eledon’s Phase 2 BESTOW trial and highlight the potential for a new approach to managing immune suppression following kidney transplantation.
Kidney transplant recipients typically require lifelong immunosuppressive medications to prevent their immune systems from rejecting donated organs. Although existing treatments have significantly improved transplant outcomes, they can produce side effects that affect patients’ daily lives and long-term health.
Eledon’s tegoprubart is designed to address this challenge by targeting CD40 ligand, a protein involved in activating immune responses. Unlike traditional immunosuppressive therapies, the investigational antibody aims to regulate immune activity through a different biological pathway.
The latest BESTOW findings focused on patient-reported outcomes, including physical symptoms, emotional well-being, and overall quality of life during the first year following transplantation.
Researchers evaluated patients using two established assessment tools: the Modified Transplant Symptom Occurrence and Symptom Distress Scale and the Kidney Disease Quality of Life Short Form.
At 12 months, patients receiving tegoprubart demonstrated continued improvements in overall symptom occurrence, while patients treated with tacrolimus experienced a slight worsening compared with their baseline measurements.
Tegoprubart also showed greater symptom improvement in 22 of 23 categories where differences between the treatment groups were observed. These included neurological, gastrointestinal, metabolic, and physical symptoms.
One of the most notable findings involved the Kidney Disease Quality of Life assessment. Patients receiving tegoprubart reported an average nine-point improvement on the Symptoms and Problems Scale, compared with a 3.3-point improvement among patients receiving tacrolimus.
The difference was statistically significant, with Eledon noting that a change of three to five points on the scale can be considered clinically meaningful.
Additional findings suggested potential benefits for mental well-being. Patients treated with tegoprubart experienced a 1.5-point improvement in the mental component summary score, compared with a 1.6-point decline in the tacrolimus group.
The findings suggest that tegoprubart’s potential benefits may extend beyond preventing organ rejection to improving how transplant recipients feel and function in everyday life.
For Eledon, the results provide additional evidence supporting the differentiated clinical profile of its lead drug candidate. Previous BESTOW findings addressed measures of efficacy, kidney function, and safety, while the newly presented data provide further insight into the patient experience.
The development is relevant to investors because kidney transplantation represents a specialized therapeutic market in which effective treatments that reduce medication-related complications could address an important unmet medical need.
However, tegoprubart remains investigational and has not received regulatory approval. Additional clinical development and regulatory review will be necessary before its potential commercial use can be established.
Eledon is also exploring the broader applications of its anti-CD40L technology across other transplantation settings and immune-related conditions, including islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis.
The latest results underscore growing interest in developing more targeted immunosuppressive treatments that balance the prevention of organ rejection with patients’ long-term quality of life.
For small-cap biotechnology investors, Eledon’s findings represent another clinical development milestone as the company works to advance tegoprubart and demonstrate its potential as an alternative to existing kidney transplant therapies.
Take a moment to read more equity research on Eledon Pharmaceuticals here.
